Advertisement

Hormones

, Volume 14, Issue 1, pp 154–159 | Cite as

Papillary thyroid cancer in a struma ovarii: a report of a rare case

  • Eleonora Monti
  • Lorenzo Mortara
  • Simonetta Zupo
  • Mariella Dono
  • Francesco Minuto
  • Mauro Truini
  • Mehrdad Naseri
  • Massimo Giusti
Case report

Abstract

After removal of an ovarian mass in a 43-year-old woman, a struma ovarii was diagnosed. Within this teratoma, a papillary thyroid cancer was found. The tumor was negative for BRAF, NRAS, KRAS, PIK3CA and c-KIT mutations on molecular analysis. Thyroid function and morphology were normal. Thyroidectomy, L-T4 TSH-suppressive therapy and rhTSH-induced radioiodine ablation were performed. So far, the follow-up has been favorable. This is the first case of thyroid cancer in a struma ovarii in which mutations of PIK3CA exons 9 and 20, and c-KIT exons 9, 11 and 13 have been evaluated and the third in which ablation has been performed under rhTSH. The prognosis of patients with thyroid cancer in a struma ovarii is generally poor. In our patient, as in those who undergo ablative radioactive iodine therapy, this was not the case.

Key words

Papillary carcinoma rhTSH Struma ovarii Teratoma 

References

  1. 1.
    Checrallah A, Medlej R, Saadè C, Khayat G, Halaby G, 2001 Malignant struma ovarii: an unusual presentation. Thyroid 11: 889–892.CrossRefGoogle Scholar
  2. 2.
    Rotman-Pikielny P, Reynolds J, Barker W, Yen P, Skarulis M, Sarlis N, 2000 Recombinant human thyrotropin for the diagnosis and treatment of a highly functional metastatic struma ovarii. J Clin Endocrinol Metab 85: 237–244.PubMedGoogle Scholar
  3. 3.
    Simkin PH, Ramirez LA, Zweing SL, et al, 1999 Monomorphic teratoma of the ovary: a rare case of triiodothyronine toxicosis. Thyroid 9: 949–954.CrossRefGoogle Scholar
  4. 4.
    Stanojievic B, Dzodic R, Saenko V, et al, 2012 Unilateral follicular variant of papillary thyroid carcinoma with unique KRAS mutation in struma ovarii in bilateral ovarian teratoma: a rare case report. BMC Cancer 12: 224–229.CrossRefGoogle Scholar
  5. 5.
    Pardo-Mindan FJ, Vazquez JJ, 1993 Malignant struma ovarii. Light and electron microscopic study. Cancer 51: 337–343.CrossRefGoogle Scholar
  6. 6.
    Shrimali RK, Shaikh G, Reed NS, 2012 Malignant struma ovarii: the west of Scotland experience and review of literature with focus on postoperative management. J Med Imaging Radiat Oncol 56: 478–482.CrossRefGoogle Scholar
  7. 7.
    Jean S, Tanyi JL, Montone K, McGrath C, Martines Lage-Alvarez M, Chu CS, 2012 Papillary thyroid cancer arising in struma ovarii. J Obstetrics Gynecol 32: 222–226.CrossRefGoogle Scholar
  8. 8.
    De Simone CP, Lele SM, Modestt SC, 2003 Malignant struma ovarii: a case report and analysis of cases reported in literature with focus on survival and 131 I therapy. Gynecol Oncol 89: 543–548.CrossRefGoogle Scholar
  9. 9.
    Schmidt J, Derr V, Heinrich MC, et al, 2007 BRAF in papillary thyroid carcinoma of ovary (struma ovarii). Am J Surg Pathol 31: 1337–1343.CrossRefGoogle Scholar
  10. 10.
    Xing M, 2013 BRAF V600E mutation and papillary thyroid cancer. JAMA 7: 310–535.Google Scholar
  11. 11.
    Melillo RM, Castellone MD, Guarino V, et al, 2005 The RET/PTC-RAS-BRAF linear signalling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest 115: 1068–1081.CrossRefGoogle Scholar
  12. 12.
    Romei C, Elisei R, 2012 RET/PTC Translocations and clinic-pathological features in human papillary thyroid carcinoma. Front Endocrinol 3: 54.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2015

Authors and Affiliations

  • Eleonora Monti
    • 1
  • Lorenzo Mortara
    • 1
  • Simonetta Zupo
    • 2
  • Mariella Dono
    • 2
  • Francesco Minuto
    • 1
  • Mauro Truini
    • 2
  • Mehrdad Naseri
    • 3
  • Massimo Giusti
    • 1
  1. 1.Dipartimento di Medicina Interna, Cattedra di EndocrinologiaUniversity of Genova, ItalyGenoaItaly
  2. 2.Department of PathologyIRCCS IST Azienda Ospedaliera Universitaria “San Martino”GenoaItaly
  3. 3.Department of Nuclear MedicineE.O. Ospedali GallieraGenoaItaly

Personalised recommendations